IRCT20220720055510N1
Recruiting
Phase 2
The effect of Liraglutide on clinical and paraclinical symptoms in patients with polycystic ovary syndrome with high body mass index in patients referred to Shahrekord endocrinology clinics
Shahre-kord University of Medical Sciences0 sites35 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shahre-kord University of Medical Sciences
- Enrollment
- 35
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women with polycystic ovary syndrome between the ages of 18 and 45 years,
- •Written and oral consent is obtained from patients to participate in the study
- •Do not have chronic physical diseases (except polycystic ovary syndrome) and mental diseases.
- •According to the patient, there is no long\-term use of drugs.
- •Body mass index is more than 25 kg/m2\.
Exclusion Criteria
- •suffering from other causes of hyperandrogenism such as congenital adrenal hyperplasia, Cushing's syndrome, ovarian or adrenal tumor.
- •Taking drugs that lead to side effects such as menstrual disorders, hirsutism or acne, or affect the profile of fat or blood sugar in the last 3 months, such as OCP, thiazides, corten, metformin, etc.
- •be pregnant.
- •Have a history of previous pancreatitis.
- •Have a family history of medullary thyroid carcinoma (mtc).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A comparative study of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health-Related Quality-of-life(HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycemic Agents (OHA's)+ high doses of insulin. - Liraglutide & Acarbose effect on HbA1c, Wt and HRQOL in type2 DiabetesType-2 Diabetes MellitusEUCTR2010-020193-42-GBHywel DdA Health Borad66
Completed
Not Applicable
Effect of the combination therapy of liraglutide, a GLP-1 receptor analog, and IDegAsp in patients with type 2 diabetesType2 diabetesJPRN-UMIN000033511Yokohama City University Medical Center Department of Endocrinology and Diabetes60
Completed
Phase 3
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes; A 52-week randomised, treat-to-target, placebo-controlled, double-blinded, parallelgroup, multinational, multi-centre trialdiabetes10018424NL-OMON38605ovo Nordisk50
Active, not recruiting
Phase 1
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 16.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2012-003580-21-NOovo Nordisk A/S1,398
Active, not recruiting
Not Applicable
The efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 16.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2012-003580-21-SEovo Nordisk A/S1,404